COMMUNIQUÉS West-GlobeNewswire

StateHouse Reports Second Quarter 2024 Financial Results

29/08/2024 - 22:30

Q2 2024 Net Revenue Increase d 10% to $27.8 Million and Gross Margin Remains Strong at 50.8 % Achieved Positive Net Income of $0.2 Million and Adjusted EBITDA of $4.9 Million in Q2 2024 SAN DIEGO and TORONTO, Aug. 29, [...]

WORK Medical Technology Group LTD Announces Partial Exercise of Underwriters’ Over-Allotment Option

29/08/2024 - 22:30

Hangzhou, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (the “Company”), a supplier of medical devices in China, today announced the underwriter of its initial public offering [...]

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

29/08/2024 - 22:25

Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

29/08/2024 - 22:25

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]

Kane Biotech Announces Second Quarter 2024 Financial Results

29/08/2024 - 22:15

Company Realizes $10.4M Gain on the Sale of STEM WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second [...]

Sana Biotechnology to Present at September 2024 Investor Conferences

29/08/2024 - 22:05

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its [...]

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

29/08/2024 - 22:05

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple [...]

Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024

29/08/2024 - 22:05

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29/08/2024 - 22:05

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29/08/2024 - 22:01

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly [...]

Cytokinetics to Participate in September Investor Conferences

29/08/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in September: [...]

Radiance BioPharma sponsoring Investor Cruise Event 2024

29/08/2024 - 21:30

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced that Robert K. Brooks [...]

EssilorLuxottica: successful Euro 2 billion bond issuance at 2.99%

29/08/2024 - 19:46

NOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR [...]

EssilorLuxottica: Succès du placement d'une émission obligataire de 2 milliards d'euros à 2,99 %

29/08/2024 - 19:46

NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMÉRIQUE, AU CANADA, EN AUSTRALIE, AU JAPON, EN AFRIQUE DU SUD OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE IL SERAIT ILLÉGAL DE LE [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024

29/08/2024 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024

29/08/2024 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]

RAMSAY SANTE : Provisional annual results at the end of June 2024

29/08/2024 - 17:35

PRESS RELEASE Paris, 29 th August 2024 Provisional annual results at the end of June 2024 As a mission-driven company, Ramsay Santé, thanks to its employees and medical community, is committed to expanding its [...]

RAMSAY SANTE : résultats annuels provisoires à fin juin 2024

29/08/2024 - 17:35

COMMUNIQUÉ DE PRESSE Paris, le 29 août 2024 Résultats annuels provisoires à fin juin 2024 Entreprise à mission, Ramsay Santé, grâce à ses collaborateurs et sa communauté médicale, s’engage à poursuivre et accélérer dans [...]

iTeos annonce sa participation aux prochaines journées Investisseurs

29/08/2024 - 17:06

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 29 août 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS) (« iTeos »), une société biopharmaceutique au stade clinique, pionnière dans la découverte et le [...]